Results 251 to 260 of about 24,361,159 (357)
Human dignity and ontological foundations: a philosophical perspective for the health professions. [PDF]
Frantz P, Rego F, Barbas S.
europepmc +1 more source
Activin A programs the differentiation of human TFH cells
Michela Locci +6 more
openalex +1 more source
Next‐generation proteomics improves lung cancer risk prediction
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj +4 more
wiley +1 more source
Crystal structure of apo human spermidine synthase reveals dynamic rearrangement at the active site. [PDF]
Fagbohun OO, Canfield MA, Clinger JA.
europepmc +1 more source
Prescription for Failure: Health & Intellectual Property in the Dominican Republic [PDF]
Georgetown University Law Center, Human Rights Institute
core +1 more source
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
The para<sup>bss1</sup> Drosophila melanogaster as Model for Chronic Nociception: Insights Into Cannabidiol Analgesic Effects. [PDF]
Malta SM +7 more
europepmc +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source

